The Journal of pediatrics · 2026
Efficacy and Safety of Titrated High-Dose Cholecalciferol Supplementation in Children and Young Adult Patients with Inflammatory Bowel Disease.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gordon Rebecca J, Vishwanath Vineet, Lavoie Ashley, Mishra Ria, Rufo Paul A
Аннотация
OBJECTIVE: To assess the safety and efficacy of high-dose, oral cholecalciferol supplementation in children and young adults with inflammatory bowel disease treated with infliximab or vedolizumab.
STUDY DESIGN: This was a prospective, longitudinal (1 year), open-label study of directly observed high-dose oral cholecalciferol administered every 4-8 weeks. Participants received either 100 000 IU every 4-6 weeks or 200 000 IU every 6-8 weeks, depending on the participant's infusion schedule. Dosing was titrated to a goal 25-hydroxyvitamin D (25-OHD) trough level of 40-60 ng/mL. Safety was assessed by spot urinary calcium and creatinine, and serum calcium levels.
RESULTS: Participants' serum 25-OHD levels increased by a mean of 18.1 ng/mL (P < .001). At study conclusion, 58% (P < .001) and 91% (P < .001) of participants had 25-OHD levels greater than 40 ng/mL and 30 ng/mL, respectively. The response to cholecalciferol did not differ between patients with Crohn's disease or ulcerative colitis (P = .74). No adverse effects were observed, including changes in serum or urinary calcium levels. Mean spot urinary calcium to creatinine ratio 0.10 at baseline and 0.09 at study conclusion (P = .26).
CONCLUSIONS: High-dose, intermittent cholecalciferol is a safe and effective approach to achieving and maintaining adequate 25-OHD in young patients with inflammatory bowel disease.
TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04331639.
STUDY DESIGN: This was a prospective, longitudinal (1 year), open-label study of directly observed high-dose oral cholecalciferol administered every 4-8 weeks. Participants received either 100 000 IU every 4-6 weeks or 200 000 IU every 6-8 weeks, depending on the participant's infusion schedule. Dosing was titrated to a goal 25-hydroxyvitamin D (25-OHD) trough level of 40-60 ng/mL. Safety was assessed by spot urinary calcium and creatinine, and serum calcium levels.
RESULTS: Participants' serum 25-OHD levels increased by a mean of 18.1 ng/mL (P < .001). At study conclusion, 58% (P < .001) and 91% (P < .001) of participants had 25-OHD levels greater than 40 ng/mL and 30 ng/mL, respectively. The response to cholecalciferol did not differ between patients with Crohn's disease or ulcerative colitis (P = .74). No adverse effects were observed, including changes in serum or urinary calcium levels. Mean spot urinary calcium to creatinine ratio 0.10 at baseline and 0.09 at study conclusion (P = .26).
CONCLUSIONS: High-dose, intermittent cholecalciferol is a safe and effective approach to achieving and maintaining adequate 25-OHD in young patients with inflammatory bowel disease.
TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04331639.